NCT01899092View on ClinicalTrials.gov

Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2016

Conditions
Hepatitis C
Interventions
DRUG

TT-034

The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.

Trial Locations (4)

27710

Duke Clinical Research Institute, Durham

75203

The Liver Institute at Methodist Dallas, Dallas

78215

The Texas Liver Institute, San Antonio

92103

UCSD Antiviral Research Center, San Diego

All Listed Sponsors
lead

Tacere Therapeutics, Inc.

INDUSTRY

NCT01899092 - Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter